Jefferies Group set a $86.00 price objective on Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) in a research note published on Wednesday. The brokerage currently has a a buy rating on the biopharmaceutical company’s stock.
Several other brokerages also recently commented on ALNY. Needham & Company LLC restated a buy rating and set a $152.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, August 5th. Cowen and Company restated a buy rating and set a $150.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Sunday, August 7th. Janney Montgomery Scott assumed coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, September 28th. They set a neutral rating and a $74.00 price objective for the company. Goldman Sachs Group Inc. restated a neutral rating and set a $65.00 price objective (up from $63.00) on shares of Alnylam Pharmaceuticals in a research report on Wednesday, August 10th. Finally, Zacks Investment Research upgraded shares of Alnylam Pharmaceuticals from a sell rating to a buy rating and set a $85.00 price objective for the company in a research report on Tuesday, August 9th. Three research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The company has a consensus rating of Buy and an average target price of $110.14.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 68.23 on Wednesday. Alnylam Pharmaceuticals has a 52 week low of $49.96 and a 52 week high of $110.75. The firm’s market cap is $5.85 billion. The company’s 50-day moving average price is $73.16 and its 200 day moving average price is $66.37.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.05) EPS for the quarter, beating the consensus estimate of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative net margin of 1,204.91% and a negative return on equity of 29.60%. The business earned $8.70 million during the quarter, compared to the consensus estimate of $8.09 million. During the same period in the previous year, the business earned ($0.85) earnings per share. The company’s revenue was up .2% on a year-over-year basis. On average, equities analysts anticipate that Alnylam Pharmaceuticals will post ($4.64) earnings per share for the current year.
In related news, CEO John Maraganore sold 30,151 shares of the business’s stock in a transaction on Wednesday, July 20th. The shares were sold at an average price of $64.69, for a total value of $1,950,468.19. Following the sale, the chief executive officer now owns 148,465 shares of the company’s stock, valued at $9,604,200.85. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 4.00% of the stock is currently owned by corporate insiders.
Several hedge funds have recently modified their holdings of the company. Nisa Investment Advisors LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at $128,000. Seven Eight Capital LLC boosted its stake in shares of Alnylam Pharmaceuticals by 200.0% in the first quarter. Seven Eight Capital LLC now owns 2,700 shares of the biopharmaceutical company’s stock valued at $169,000 after buying an additional 1,800 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at $175,000. Bank of Montreal Can acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at $193,000. Finally, BlueMountain Capital Management LLC boosted its stake in shares of Alnylam Pharmaceuticals by 89.3% in the first quarter. BlueMountain Capital Management LLC now owns 3,179 shares of the biopharmaceutical company’s stock valued at $200,000 after buying an additional 1,500 shares in the last quarter. 85.96% of the stock is currently owned by institutional investors.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.